APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

HIV Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global HIV Vaccines Market Analysis and Forecast 2026-2032

Report ID 173998830220 December 2025192 pages

Choose your research edition.

Industry ResearchHIV Vaccines Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal HIV Vaccines Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal HIV Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal HIV Vaccines Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal HIV Vaccines Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global HIV Vaccines market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for HIV Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for HIV Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for HIV Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for HIV Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of HIV Vaccines include Sanofi, Glaxosmithkline, Paxvax, Janssen Global Services, Inovio Pharmaceuticals, Geovax, Genecure, Bionor Pharma and Argos Therapeutics, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for HIV Vaccines, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of HIV Vaccines, also provides the revenue of main regions and countries. Of the upcoming market potential for HIV Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the HIV Vaccines revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global HIV Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for HIV Vaccines revenue, projected growth trends, production technology, application and end-user industry.

HIV Vaccines Segment by Company

Sanofi

Glaxosmithkline

Paxvax

Janssen Global Services

Inovio Pharmaceuticals

Geovax

Genecure

Bionor Pharma

Argos Therapeutics

HIV Vaccines Segment by Type

Phase I

Phase II

Phase III

HIV Vaccines Segment by Application

Research Institute

Others

HIV Vaccines Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global HIV Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of HIV Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of HIV Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of HIV Vaccines in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of HIV Vaccines company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, HIV Vaccines revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global HIV Vaccines Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Phase I Major Player Table 3. Phase II Major Player Table 4. Phase III Major Player Table 5. Global HIV Vaccines Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Research Institute Major Player Table 7. Others Major Player Table 8. HIV Vaccines Industry Trends Table 9. HIV Vaccines Industry Drivers Table 10. HIV Vaccines Industry Opportunities and Challenges Table 11. HIV Vaccines Industry Restraints Table 12. Global HIV Vaccines Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global HIV Vaccines Market Size by Region (2021-2026) & (US$ Million) Table 14. Global HIV Vaccines Market Share by Region (2021-2026) Table 15. Global HIV Vaccines Market Size by Region (2027-2032) & (US$ Million) Table 16. Global HIV Vaccines Market Share by Region (2027-2032) Table 17. Global HIV Vaccines Revenue by Players (US$ Million) & (2021-2026) Table 18. Global HIV Vaccines Revenue Market Share by Players (2021-2026) Table 19. Global HIV Vaccines Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global HIV Vaccines Key Players Headquarters & Area Served Table 21. Global HIV Vaccines Players, Product Type & Application Table 22. Global HIV Vaccines Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global HIV Vaccines by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global HIV Vaccines Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global HIV Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 27. Global HIV Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 28. Global HIV Vaccines Revenue Market Share by Type (2021-2026) Table 29. Global HIV Vaccines Revenue Market Share by Type (2027-2032) Table 30. Global HIV Vaccines Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global HIV Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 32. Global HIV Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 33. Global HIV Vaccines Revenue Market Share by Application (2021-2026) Table 34. Global HIV Vaccines Revenue Market Share by Application (2027-2032) Table 35. Sanofi Company Information Table 36. Sanofi Business Overview Table 37. Sanofi HIV Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Sanofi HIV Vaccines Product Portfolio Table 39. Sanofi Recent Development Table 40. Glaxosmithkline Company Information Table 41. Glaxosmithkline Business Overview Table 42. Glaxosmithkline HIV Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Glaxosmithkline HIV Vaccines Product Portfolio Table 44. Glaxosmithkline Recent Development Table 45. Paxvax Company Information Table 46. Paxvax Business Overview Table 47. Paxvax HIV Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Paxvax HIV Vaccines Product Portfolio Table 49. Paxvax Recent Development Table 50. Janssen Global Services Company Information Table 51. Janssen Global Services Business Overview Table 52. Janssen Global Services HIV Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Janssen Global Services HIV Vaccines Product Portfolio Table 54. Janssen Global Services Recent Development Table 55. Inovio Pharmaceuticals Company Information Table 56. Inovio Pharmaceuticals Business Overview Table 57. Inovio Pharmaceuticals HIV Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Inovio Pharmaceuticals HIV Vaccines Product Portfolio Table 59. Inovio Pharmaceuticals Recent Development Table 60. Geovax Company Information Table 61. Geovax Business Overview Table 62. Geovax HIV Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Geovax HIV Vaccines Product Portfolio Table 64. Geovax Recent Development Table 65. Genecure Company Information Table 66. Genecure Business Overview Table 67. Genecure HIV Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Genecure HIV Vaccines Product Portfolio Table 69. Genecure Recent Development Table 70. Bionor Pharma Company Information Table 71. Bionor Pharma Business Overview Table 72. Bionor Pharma HIV Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Bionor Pharma HIV Vaccines Product Portfolio Table 74. Bionor Pharma Recent Development Table 75. Argos Therapeutics Company Information Table 76. Argos Therapeutics Business Overview Table 77. Argos Therapeutics HIV Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Argos Therapeutics HIV Vaccines Product Portfolio Table 79. Argos Therapeutics Recent Development Table 80. North America HIV Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 81. North America HIV Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 82. North America HIV Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 83. North America HIV Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 84. North America HIV Vaccines Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 85. North America HIV Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 86. North America HIV Vaccines Revenue by Country (US$ Million) & (2027-2032) Table 87. Europe HIV Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 88. Europe HIV Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 89. Europe HIV Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 90. Europe HIV Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 91. Europe HIV Vaccines Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 92. Europe HIV Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 93. Europe HIV Vaccines Revenue by Country (US$ Million) & (2027-2032) Table 94. China HIV Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 95. China HIV Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 96. China HIV Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 97. China HIV Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 98. Asia HIV Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 99. Asia HIV Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 100. Asia HIV Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 101. Asia HIV Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 102. Asia HIV Vaccines Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 103. Asia HIV Vaccines Revenue by Region (US$ Million) & (2021-2026) Table 104. Asia HIV Vaccines Revenue by Region (US$ Million) & (2027-2032) Table 105. SAMEA HIV Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 106. SAMEA HIV Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 107. SAMEA HIV Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 108. SAMEA HIV Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 109. SAMEA HIV Vaccines Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 110. SAMEA HIV Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 111. SAMEA HIV Vaccines Revenue by Country (US$ Million) & (2027-2032) Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. HIV Vaccines Image Figure 2. Global HIV Vaccines Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global HIV Vaccines Market Size Share 2021 VS 2025 VS 2032 Figure 4. Phase I Image Figure 5. Phase II Image Figure 6. Phase III Image Figure 7. Global HIV Vaccines Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global HIV Vaccines Market Size Share 2021 VS 2025 VS 2032 Figure 9. Research Institute Image Figure 10. Others Image Figure 11. Global HIV Vaccines Market Size (US$ Million) & (2021-2032) Figure 12. Global HIV Vaccines Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global HIV Vaccines Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global HIV Vaccines Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global HIV Vaccines Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global HIV Vaccines Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global HIV Vaccines Revenue Market Share by Type (2021-2032) Figure 19. Global HIV Vaccines Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global HIV Vaccines Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global HIV Vaccines Revenue Market Share by Application (2021-2032) Figure 22. North America HIV Vaccines Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America HIV Vaccines Revenue Share by Type (2021-2032) Figure 24. North America HIV Vaccines Revenue Share by Application (2021-2032) Figure 25. North America HIV Vaccines Revenue Share by Country (2021-2032) Figure 26. United States HIV Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada HIV Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico HIV Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe HIV Vaccines Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe HIV Vaccines Revenue Share by Type (2021-2032) Figure 31. Europe HIV Vaccines Revenue Share by Application (2021-2032) Figure 32. Europe HIV Vaccines Revenue Share by Country (2021-2032) Figure 33. Germany HIV Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France HIV Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. HIV Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy HIV Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain HIV Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia HIV Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands HIV Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries HIV Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China HIV Vaccines Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China HIV Vaccines Revenue Share by Type (2021-2032) Figure 43. China HIV Vaccines Revenue Share by Application (2021-2032) Figure 44. Asia HIV Vaccines Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia HIV Vaccines Revenue Share by Type (2021-2032) Figure 46. Asia HIV Vaccines Revenue Share by Application (2021-2032) Figure 47. Asia HIV Vaccines Revenue Share by Region (2021-2032) Figure 48. Japan HIV Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea HIV Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India HIV Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia HIV Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan HIV Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia HIV Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA HIV Vaccines Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA HIV Vaccines Revenue Share by Type (2021-2032) Figure 56. SAMEA HIV Vaccines Revenue Share by Application (2021-2032) Figure 57. SAMEA HIV Vaccines Revenue Share by Country (2021-2032) Figure 58. Brazil HIV Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina HIV Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile HIV Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia HIV Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru HIV Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia HIV Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel HIV Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE HIV Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey HIV Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran HIV Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt HIV Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Phase I
  • Phase II
  • Phase III
Applications
  • Research Institute
  • Others
Companies covered
  • Sanofi
  • Glaxosmithkline
  • Paxvax
  • Janssen Global Services
  • Inovio Pharmaceuticals
  • Geovax
  • Genecure
  • Bionor Pharma
  • Argos Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 HIV Vaccines Market by Type
  3. 1.2.1 Global HIV Vaccines Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Phase I
  5. 1.2.3 Phase II
  6. 1.2.4 Phase III
  7. 1.3 HIV Vaccines Market by Application
  8. 1.3.1 Global HIV Vaccines Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Research Institute
  10. 1.3.3 Others
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 HIV Vaccines Market Dynamics
  1. 2.1 HIV Vaccines Industry Trends
  2. 2.2 HIV Vaccines Industry Drivers
  3. 2.3 HIV Vaccines Industry Opportunities and Challenges
  4. 2.4 HIV Vaccines Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global HIV Vaccines Market Perspective (2021-2032)
  2. 3.2 Global HIV Vaccines Growth Trends by Region
  3. 3.2.1 Global HIV Vaccines Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global HIV Vaccines Market Size by Region (2021-2026)
  5. 3.2.3 Global HIV Vaccines Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global HIV Vaccines Revenue by Players
  2. 4.1.1 Global HIV Vaccines Revenue by Players (2021-2026)
  3. 4.1.2 Global HIV Vaccines Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global HIV Vaccines Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global HIV Vaccines Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global HIV Vaccines Key Players Headquarters & Area Served
  7. 4.4 Global HIV Vaccines Players, Product Type & Application
  8. 4.5 Global HIV Vaccines Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global HIV Vaccines Market CR5 and HHI
  11. 4.6.3 2025 HIV Vaccines Tier 1, Tier 2, and Tier 3
5 HIV Vaccines Market Size by Type
  1. 5.1 Global HIV Vaccines Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global HIV Vaccines Revenue by Type (2021-2032)
  3. 5.3 Global HIV Vaccines Revenue Market Share by Type (2021-2032)
6 HIV Vaccines Market Size by Application
  1. 6.1 Global HIV Vaccines Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global HIV Vaccines Revenue by Application (2021-2032)
  3. 6.3 Global HIV Vaccines Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Sanofi
  2. 7.1.1 Sanofi Company Information
  3. 7.1.2 Sanofi Business Overview
  4. 7.1.3 Sanofi HIV Vaccines Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Sanofi HIV Vaccines Product Portfolio
  6. 7.1.5 Sanofi Recent Developments
  7. 7.2 Glaxosmithkline
  8. 7.2.1 Glaxosmithkline Company Information
  9. 7.2.2 Glaxosmithkline Business Overview
  10. 7.2.3 Glaxosmithkline HIV Vaccines Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Glaxosmithkline HIV Vaccines Product Portfolio
  12. 7.2.5 Glaxosmithkline Recent Developments
  13. 7.3 Paxvax
  14. 7.3.1 Paxvax Company Information
  15. 7.3.2 Paxvax Business Overview
  16. 7.3.3 Paxvax HIV Vaccines Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Paxvax HIV Vaccines Product Portfolio
  18. 7.3.5 Paxvax Recent Developments
  19. 7.4 Janssen Global Services
  20. 7.4.1 Janssen Global Services Company Information
  21. 7.4.2 Janssen Global Services Business Overview
  22. 7.4.3 Janssen Global Services HIV Vaccines Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Janssen Global Services HIV Vaccines Product Portfolio
  24. 7.4.5 Janssen Global Services Recent Developments
  25. 7.5 Inovio Pharmaceuticals
  26. 7.5.1 Inovio Pharmaceuticals Company Information
  27. 7.5.2 Inovio Pharmaceuticals Business Overview
  28. 7.5.3 Inovio Pharmaceuticals HIV Vaccines Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Inovio Pharmaceuticals HIV Vaccines Product Portfolio
  30. 7.5.5 Inovio Pharmaceuticals Recent Developments
  31. 7.6 Geovax
  32. 7.6.1 Geovax Company Information
  33. 7.6.2 Geovax Business Overview
  34. 7.6.3 Geovax HIV Vaccines Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Geovax HIV Vaccines Product Portfolio
  36. 7.6.5 Geovax Recent Developments
  37. 7.7 Genecure
  38. 7.7.1 Genecure Company Information
  39. 7.7.2 Genecure Business Overview
  40. 7.7.3 Genecure HIV Vaccines Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Genecure HIV Vaccines Product Portfolio
  42. 7.7.5 Genecure Recent Developments
  43. 7.8 Bionor Pharma
  44. 7.8.1 Bionor Pharma Company Information
  45. 7.8.2 Bionor Pharma Business Overview
  46. 7.8.3 Bionor Pharma HIV Vaccines Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Bionor Pharma HIV Vaccines Product Portfolio
  48. 7.8.5 Bionor Pharma Recent Developments
  49. 7.9 Argos Therapeutics
  50. 7.9.1 Argos Therapeutics Company Information
  51. 7.9.2 Argos Therapeutics Business Overview
  52. 7.9.3 Argos Therapeutics HIV Vaccines Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Argos Therapeutics HIV Vaccines Product Portfolio
  54. 7.9.5 Argos Therapeutics Recent Developments
8 North America
  1. 8.1 North America HIV Vaccines Revenue (2021-2032)
  2. 8.2 North America HIV Vaccines Revenue by Type (2021-2032)
  3. 8.2.1 North America HIV Vaccines Revenue by Type (2021-2026)
  4. 8.2.2 North America HIV Vaccines Revenue by Type (2027-2032)
  5. 8.3 North America HIV Vaccines Revenue Share by Type (2021-2032)
  6. 8.4 North America HIV Vaccines Revenue by Application (2021-2032)
  7. 8.4.1 North America HIV Vaccines Revenue by Application (2021-2026)
  8. 8.4.2 North America HIV Vaccines Revenue by Application (2027-2032)
  9. 8.5 North America HIV Vaccines Revenue Share by Application (2021-2032)
  10. 8.6 North America HIV Vaccines Revenue by Country
  11. 8.6.1 North America HIV Vaccines Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America HIV Vaccines Revenue by Country (2021-2026)
  13. 8.6.3 North America HIV Vaccines Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe HIV Vaccines Revenue (2021-2032)
  2. 9.2 Europe HIV Vaccines Revenue by Type (2021-2032)
  3. 9.2.1 Europe HIV Vaccines Revenue by Type (2021-2026)
  4. 9.2.2 Europe HIV Vaccines Revenue by Type (2027-2032)
  5. 9.3 Europe HIV Vaccines Revenue Share by Type (2021-2032)
  6. 9.4 Europe HIV Vaccines Revenue by Application (2021-2032)
  7. 9.4.1 Europe HIV Vaccines Revenue by Application (2021-2026)
  8. 9.4.2 Europe HIV Vaccines Revenue by Application (2027-2032)
  9. 9.5 Europe HIV Vaccines Revenue Share by Application (2021-2032)
  10. 9.6 Europe HIV Vaccines Revenue by Country
  11. 9.6.1 Europe HIV Vaccines Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe HIV Vaccines Revenue by Country (2021-2026)
  13. 9.6.3 Europe HIV Vaccines Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China HIV Vaccines Revenue (2021-2032)
  2. 10.2 China HIV Vaccines Revenue by Type (2021-2032)
  3. 10.2.1 China HIV Vaccines Revenue by Type (2021-2026)
  4. 10.2.2 China HIV Vaccines Revenue by Type (2027-2032)
  5. 10.3 China HIV Vaccines Revenue Share by Type (2021-2032)
  6. 10.4 China HIV Vaccines Revenue by Application (2021-2032)
  7. 10.4.1 China HIV Vaccines Revenue by Application (2021-2026)
  8. 10.4.2 China HIV Vaccines Revenue by Application (2027-2032)
  9. 10.5 China HIV Vaccines Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia HIV Vaccines Revenue (2021-2032)
  2. 11.2 Asia HIV Vaccines Revenue by Type (2021-2032)
  3. 11.2.1 Asia HIV Vaccines Revenue by Type (2021-2026)
  4. 11.2.2 Asia HIV Vaccines Revenue by Type (2027-2032)
  5. 11.3 Asia HIV Vaccines Revenue Share by Type (2021-2032)
  6. 11.4 Asia HIV Vaccines Revenue by Application (2021-2032)
  7. 11.4.1 Asia HIV Vaccines Revenue by Application (2021-2026)
  8. 11.4.2 Asia HIV Vaccines Revenue by Application (2027-2032)
  9. 11.5 Asia HIV Vaccines Revenue Share by Application (2021-2032)
  10. 11.6 Asia HIV Vaccines Revenue by Country
  11. 11.6.1 Asia HIV Vaccines Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia HIV Vaccines Revenue by Country (2021-2026)
  13. 11.6.3 Asia HIV Vaccines Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA HIV Vaccines Revenue (2021-2032)
  2. 12.2 SAMEA HIV Vaccines Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA HIV Vaccines Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA HIV Vaccines Revenue by Type (2027-2032)
  5. 12.3 SAMEA HIV Vaccines Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA HIV Vaccines Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA HIV Vaccines Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA HIV Vaccines Revenue by Application (2027-2032)
  9. 12.5 SAMEA HIV Vaccines Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA HIV Vaccines Revenue by Country
  11. 12.6.1 SAMEA HIV Vaccines Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA HIV Vaccines Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA HIV Vaccines Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst